Abstracts tagged "biomarkers and canakinumab"

Abstract Number: 2917 • 2018 ACR/ARHP Annual Meeting
Multiplex Serum Biomarker Analysis before and during Therapy with Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis
Tanja Hinze¹, Christoph Kessel¹, Claas Hinze¹, Julia Seibert², Hermann Gram² and Dirk Foell³, ¹Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²Novartis, Basel, Switzerland, ³Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: Canakinumab (CAN), a monoclonal anti-interleukin (IL)-1β antibody, is approved for the treatment of systemic juvenile idiopathic arthritis (SJIA). CAN-treated patients with SJIA showed a…